title: Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.
abstract: This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies.Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.
authors: Department of Medical Oncology, Erciyes University Medical School, Kayseri, Turkey. metino@erciyes.edu.tr
authors: M
authors: M
authors: Ozkan
authors: V
authors: V
authors: Berk
authors: M A
authors: MA
authors: Kaplan
authors: M
authors: M
authors: Benekli
authors: U
authors: U
authors: Coskun
authors: A
authors: A
authors: Bilici
authors: M
authors: M
authors: Gumus
authors: N
authors: N
authors: Alkis
authors: F
authors: F
authors: Dane
authors: N Y
authors: NY
authors: Ozdemir
authors: D
authors: D
authors: Colak
authors: M
authors: M
authors: Dikilitas
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000188:drug therapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016879:Salvage Therapy; D043823:Taxoids / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced; D000093542:Gemcitabine
chemical_list: D018943:Anthracyclines; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine